Switch to:
Also traded in: Argentina, Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.71
NYSE:LLY's Cash-to-Debt is ranked lower than
66% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. NYSE:LLY: 0.71 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:LLY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 0.68 Max: 1.64
Current: 0.71
0.11
1.64
Equity-to-Asset 0.29
NYSE:LLY's Equity-to-Asset is ranked lower than
89% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:LLY: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:LLY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.44 Max: 0.67
Current: 0.29
0.23
0.67
Debt-to-Equity 0.97
NYSE:LLY's Debt-to-Equity is ranked lower than
86% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NYSE:LLY: 0.97 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:LLY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11  Med: 0.5 Max: 1.55
Current: 0.97
0.11
1.55
Debt-to-EBITDA 2.50
NYSE:LLY's Debt-to-EBITDA is ranked lower than
64% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. NYSE:LLY: 2.50 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:LLY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.7  Med: 1.39 Max: 241.62
Current: 2.5
0.7
241.62
Interest Coverage 15.77
NYSE:LLY's Interest Coverage is ranked lower than
66% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. NYSE:LLY: 15.77 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:LLY' s Interest Coverage Range Over the Past 10 Years
Min: 13.87  Med: 24.3 Max: 35.47
Current: 15.77
13.87
35.47
Piotroski F-Score: 6
Altman Z-Score: 3.85
Beneish M-Score: -2.90
WACC vs ROIC
6.19%
3.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.68
NYSE:LLY's Operating Margin % is ranked higher than
70% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. NYSE:LLY: 16.68 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:LLY' s Operating Margin % Range Over the Past 10 Years
Min: 13.65  Med: 22.62 Max: 29.17
Current: 16.68
13.65
29.17
Net Margin % 1.85
NYSE:LLY's Net Margin % is ranked lower than
69% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. NYSE:LLY: 1.85 )
Ranked among companies with meaningful Net Margin % only.
NYSE:LLY' s Net Margin % Range Over the Past 10 Years
Min: -10.17  Med: 15.4 Max: 21.97
Current: 1.85
-10.17
21.97
ROE % 3.43
NYSE:LLY's ROE % is ranked lower than
66% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. NYSE:LLY: 3.43 )
Ranked among companies with meaningful ROE % only.
NYSE:LLY' s ROE % Range Over the Past 10 Years
Min: -20.47  Med: 24.03 Max: 53.25
Current: 3.43
-20.47
53.25
ROA % 1.03
NYSE:LLY's ROA % is ranked lower than
64% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. NYSE:LLY: 1.03 )
Ranked among companies with meaningful ROA % only.
NYSE:LLY' s ROA % Range Over the Past 10 Years
Min: -7.39  Med: 9.69 Max: 17.34
Current: 1.03
-7.39
17.34
ROC (Joel Greenblatt) % 35.50
NYSE:LLY's ROC (Joel Greenblatt) % is ranked higher than
73% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. NYSE:LLY: 35.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:LLY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11.59  Med: 53.42 Max: 76.89
Current: 35.5
-11.59
76.89
3-Year Revenue Growth Rate 6.00
NYSE:LLY's 3-Year Revenue Growth Rate is ranked higher than
52% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NYSE:LLY: 6.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:LLY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.7  Med: 6.3 Max: 14.3
Current: 6
-5.7
14.3
3-Year EBITDA Growth Rate -3.50
NYSE:LLY's 3-Year EBITDA Growth Rate is ranked lower than
71% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NYSE:LLY: -3.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:LLY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -78.5  Med: 4.3 Max: 437.2
Current: -3.5
-78.5
437.2
GuruFocus has detected 8 Warning Signs with Eli Lilly and Co NYSE:LLY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:LLY's 30-Y Financials

Financials (Next Earnings Date: 2019-01-31 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

LLY Guru Trades in Q4 2017

Joel Greenblatt 256,537 sh (New)
Caxton Associates 16,228 sh (New)
Ray Dalio 123,940 sh (New)
Ken Fisher 3,309,599 sh (+6.45%)
Dodge & Cox 20,181,287 sh (+0.81%)
Jeremy Grantham 980,849 sh (+22.29%)
Steven Cohen 646,800 sh (+7.80%)
Jim Simons 4,272,105 sh (+5.50%)
Mairs and Power 1,014,481 sh (+3.84%)
Pioneer Investments 1,832,626 sh (+110.93%)
Murray Stahl 25,082 sh (unchged)
Vanguard Health Care Fund 26,239,267 sh (-6.66%)
HOTCHKIS & WILEY 24,900 sh (-4.96%)
Sarah Ketterer 2,880,032 sh (-4.25%)
PRIMECAP Management 55,152,577 sh (-0.95%)
Mario Gabelli 52,100 sh (-29.45%)
Eaton Vance Worldwide Health Sciences Fund 559,742 sh (-5.17%)
» More
Q1 2018

LLY Guru Trades in Q1 2018

Paul Tudor Jones 47,542 sh (New)
Ken Fisher 3,529,211 sh (+6.64%)
Dodge & Cox 21,842,117 sh (+8.23%)
Sarah Ketterer 3,705,960 sh (+28.68%)
Jeremy Grantham 1,329,349 sh (+35.53%)
Steven Cohen 898,691 sh (+38.94%)
Mairs and Power 1,039,293 sh (+2.45%)
Ray Dalio 225,798 sh (+82.18%)
HOTCHKIS & WILEY 24,900 sh (unchged)
Caxton Associates Sold Out
Vanguard Health Care Fund 24,989,415 sh (-4.76%)
Joel Greenblatt 90,625 sh (-64.67%)
Murray Stahl 24,082 sh (-3.99%)
PRIMECAP Management 54,546,783 sh (-1.10%)
Jim Simons 3,755,705 sh (-12.09%)
Pioneer Investments 1,021,968 sh (-44.23%)
Mario Gabelli 50,950 sh (-2.21%)
Eaton Vance Worldwide Health Sciences Fund 430,672 sh (-23.06%)
» More
Q2 2018

LLY Guru Trades in Q2 2018

Ken Fisher 3,710,066 sh (+5.12%)
Dodge & Cox 27,020,471 sh (+23.71%)
PRIMECAP Management 55,102,514 sh (+1.02%)
Paul Tudor Jones 51,157 sh (+7.60%)
Pioneer Investments 1,312,958 sh (+28.47%)
Ray Dalio 226,525 sh (+0.32%)
Joel Greenblatt Sold Out
Vanguard Health Care Fund 24,222,715 sh (-3.07%)
Murray Stahl 22,582 sh (-6.23%)
HOTCHKIS & WILEY 23,000 sh (-7.63%)
Sarah Ketterer 2,737,558 sh (-26.13%)
Jeremy Grantham 423,559 sh (-68.14%)
Steven Cohen 745,800 sh (-17.01%)
Mairs and Power 1,036,478 sh (-0.27%)
Mario Gabelli 49,315 sh (-3.21%)
Eaton Vance Worldwide Health Sciences Fund 341,879 sh (-20.62%)
Jim Simons 488,000 sh (-87.01%)
» More
Q3 2018

LLY Guru Trades in Q3 2018

Ken Heebner 405,000 sh (New)
Joel Greenblatt 69,828 sh (New)
Caxton Associates 2,333 sh (New)
Ken Fisher 3,726,670 sh (+0.45%)
Pioneer Investments 2,265,340 sh (+72.54%)
Paul Tudor Jones 72,929 sh (+42.56%)
Jim Simons Sold Out
Eaton Vance Worldwide Health Sciences Fund 291,701 sh (-14.68%)
Vanguard Health Care Fund 22,449,015 sh (-7.32%)
Mario Gabelli 40,765 sh (-17.34%)
PRIMECAP Management 54,791,568 sh (-0.56%)
Ray Dalio 135,421 sh (-40.22%)
Jeremy Grantham 373,459 sh (-11.83%)
Mairs and Power 938,178 sh (-9.48%)
Sarah Ketterer 1,107,572 sh (-59.54%)
HOTCHKIS & WILEY 20,600 sh (-10.43%)
Murray Stahl 21,254 sh (-5.88%)
Steven Cohen 50,000 sh (-93.30%)
Dodge & Cox 22,692,971 sh (-16.02%)
» More
» Details

Insider Trades

Latest Guru Trades with LLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:AZN, NYSE:BMY, XPAR:SAN, LSE:GSK, XTER:BAYN, TSE:4503, TSE:4519, TSE:4578, NYSE:ABBV, TSE:4568, NYSE:MRK, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:LLY.Argentina, LILY34.Brazil, LLY.France, LLY.Germany, LLY.Mexico, LLY.Switzerland, LEL.UK,
Headquarter Location:USA
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Cialis for erectile dysfunction. Also, Lilly holds a strong position in the animal healthcare market.

Guru Investment Theses on Eli Lilly and Co

Dodge & Cox Comments on Eli Lilly - Feb 13, 2018

During the second quarter of 2017, we initiated a position in Eli Lilly (NYSE:LLY), a leading drug company focused on branded pharmaceuticals and animal health products. As the only pharmaceutical company with a presence across all major drug classes in the diabetes field, it has an advantage in contracting and marketing products. Until recently, Eli Lilly was losing market share to Novo Nordisk and Sanofi in the key area of diabetes classes, given its smaller emerging markets footprint and lack of a basal insulin therapy. This trend reversed as Eli Lilly launched several new products during the last few years, and the company is now gaining share in most therapeutic areas within diabetes. Eli Lilly’s partnership with Boehringer Ingelheim, where costs and profits are shared 50/50, has been important in rejuvenating its diabetes portfolio.



After weathering two recent patent expirations, Eli Lilly is entering what could be an extended period of growth. The company’s four new drugs should each generate over $1 billion in annual sales. All of these recent product approvals have found commercial success and are driving future sales growth. If revenue grows as we expect, margins should improve significantly and boost earnings growth. The company has consistently had one of the better research and development (R&D) groups in the Pharmaceuticals industry due to its stable organization, thoughtful leadership, and high funding.



Most importantly, the company’s newly appointed CEO leads a competent management team that appears to be well aligned with the interests of long-term shareholders and capable of navigating competitive and regulatory risks. Eli Lilly was a 1.4% position in the portfolio on December 31.



From Dodge & Cox's fourth quarter 2017 shareholder letter.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about Eli Lilly and Co

Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences
Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors
NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment
Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS
Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
Lilly to Participate in Credit Suisse 27th Annual Healthcare Conference
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Ratios

vs
industry
vs
history
PE Ratio 243.33
LLY's PE Ratio is ranked lower than
99.99% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. LLY: 243.33 )
Ranked among companies with meaningful PE Ratio only.
LLY' s PE Ratio Range Over the Past 10 Years
Min: 7.44  Med: 15.38 Max: 257.91
Current: 243.33
7.44
257.91
Forward PE Ratio 19.12
LLY's Forward PE Ratio is ranked higher than
59% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. LLY: 19.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 243.33
LLY's PE Ratio without NRI is ranked lower than
99.99% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. LLY: 243.33 )
Ranked among companies with meaningful PE Ratio without NRI only.
LLY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.44  Med: 15.38 Max: 257.91
Current: 243.33
7.44
257.91
Price-to-Owner-Earnings 62.50
LLY's Price-to-Owner-Earnings is ranked lower than
99.99% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. LLY: 62.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LLY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.36  Med: 13.49 Max: 81.3
Current: 62.5
6.36
81.3
PB Ratio 9.14
LLY's PB Ratio is ranked lower than
90% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. LLY: 9.14 )
Ranked among companies with meaningful PB Ratio only.
LLY' s PB Ratio Range Over the Past 10 Years
Min: 2.52  Med: 4.21 Max: 9.83
Current: 9.14
2.52
9.83
PS Ratio 4.78
LLY's PS Ratio is ranked lower than
62% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. LLY: 4.78 )
Ranked among companies with meaningful PS Ratio only.
LLY' s PS Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.7 Max: 5.07
Current: 4.78
1.49
5.07
Price-to-Free-Cash-Flow 39.51
LLY's Price-to-Free-Cash-Flow is ranked lower than
63% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. LLY: 39.51 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LLY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.17  Med: 13.6 Max: 68.96
Current: 39.51
5.17
68.96
Price-to-Operating-Cash-Flow 19.89
LLY's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. LLY: 19.89 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LLY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.41  Med: 10.95 Max: 31.12
Current: 19.89
4.41
31.12
EV-to-EBIT 36.28
LLY's EV-to-EBIT is ranked lower than
87% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. LLY: 36.28 )
Ranked among companies with meaningful EV-to-EBIT only.
LLY' s EV-to-EBIT Range Over the Past 10 Years
Min: -303.9  Med: 11.05 Max: 44.5
Current: 36.28
-303.9
44.5
EV-to-EBITDA 24.30
LLY's EV-to-EBITDA is ranked lower than
79% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. LLY: 24.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
LLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.8  Med: 11.2 Max: 1132
Current: 24.3
4.8
1132
EV-to-Revenue 5.08
LLY's EV-to-Revenue is ranked lower than
63% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. LLY: 5.08 )
Ranked among companies with meaningful EV-to-Revenue only.
LLY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2.7 Max: 5.2
Current: 5.08
1.6
5.2
Shiller PE Ratio 39.40
LLY's Shiller PE Ratio is ranked lower than
59% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. LLY: 39.40 )
Ranked among companies with meaningful Shiller PE Ratio only.
LLY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.87  Med: 18.4 Max: 41.77
Current: 39.4
10.87
41.77
Current Ratio 1.91
LLY's Current Ratio is ranked lower than
73% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. LLY: 1.91 )
Ranked among companies with meaningful Current Ratio only.
LLY' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.56 Max: 3
Current: 1.91
0.7
3
Quick Ratio 1.53
LLY's Quick Ratio is ranked lower than
70% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. LLY: 1.53 )
Ranked among companies with meaningful Quick Ratio only.
LLY' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.21 Max: 2.38
Current: 1.53
0.53
2.38
Days Inventory 248.29
LLY's Days Inventory is ranked lower than
88% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. LLY: 248.29 )
Ranked among companies with meaningful Days Inventory only.
LLY' s Days Inventory Range Over the Past 10 Years
Min: 173.48  Med: 216.93 Max: 248.29
Current: 248.29
173.48
248.29
Days Sales Outstanding 73.06
LLY's Days Sales Outstanding is ranked higher than
56% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. LLY: 73.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
LLY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.79  Med: 55.57 Max: 73.06
Current: 73.06
49.79
73.06
Days Payable 73.06
LLY's Days Payable is ranked lower than
52% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. LLY: 73.06 )
Ranked among companies with meaningful Days Payable only.
LLY' s Days Payable Range Over the Past 10 Years
Min: 73.06  Med: 84.16 Max: 96.97
Current: 73.06
73.06
96.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.01
LLY's Dividend Yield % is ranked higher than
83% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. LLY: 2.01 )
Ranked among companies with meaningful Dividend Yield % only.
LLY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.86  Med: 3.62 Max: 6.79
Current: 2.01
1.86
6.79
Dividend Payout Ratio 4.70
LLY's Dividend Payout Ratio is ranked lower than
82% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. LLY: 4.70 )
Ranked among companies with meaningful Dividend Payout Ratio only.
LLY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.43  Med: 0.52 Max: 4.7
Current: 4.7
0.43
4.7
3-Year Dividend Growth Rate 2.00
LLY's 3-Year Dividend Growth Rate is ranked lower than
66% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. LLY: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
LLY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.9 Max: 20.2
Current: 2
0
20.2
Forward Dividend Yield % 2.01
LLY's Forward Dividend Yield % is ranked higher than
66% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. LLY: 2.01 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.14
LLY's 5-Year Yield-on-Cost % is ranked higher than
72% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. LLY: 2.14 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LLY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.98  Med: 3.86 Max: 7.24
Current: 2.14
1.98
7.24
3-Year Average Share Buyback Ratio 0.30
LLY's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. LLY: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LLY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: -0.1 Max: 2
Current: 0.3
-3.1
2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 12.63
LLY's Price-to-Tangible-Book is ranked lower than
90% of the 749 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. LLY: 12.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LLY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.22  Med: 7.01 Max: 33.46
Current: 12.63
3.22
33.46
Price-to-Intrinsic-Value-Projected-FCF 2.84
LLY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
63% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. LLY: 2.84 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LLY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.68  Med: 2.06 Max: 5.56
Current: 2.84
0.68
5.56
Price-to-Median-PS-Value 1.77
LLY's Price-to-Median-PS-Value is ranked lower than
83% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. LLY: 1.77 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LLY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.6  Med: 1.49 Max: 3.99
Current: 1.77
0.6
3.99
Price-to-Graham-Number 11.68
LLY's Price-to-Graham-Number is ranked lower than
99.99% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. LLY: 11.68 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LLY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.25  Med: 2.8 Max: 11.68
Current: 11.68
1.25
11.68
Earnings Yield (Greenblatt) % 2.76
LLY's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. LLY: 2.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LLY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.9  Med: 6.75 Max: 17.4
Current: 2.76
-2.9
17.4
Forward Rate of Return (Yacktman) % -2.88
LLY's Forward Rate of Return (Yacktman) % is ranked lower than
81% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. LLY: -2.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LLY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -19.2  Med: -1.45 Max: 31.3
Current: -2.88
-19.2
31.3

More Statistics

Revenue (TTM) (Mil) $24,277.80
EPS (TTM) $ 0.46
Beta0.64
Volatility20.20%
52-Week Range $73.69 - 119.84
Shares Outstanding (Mil)1,059.32

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 24,451 25,208 26,315
EBIT (Mil $) 5,764 6,932 7,959
EBITDA (Mil $) 7,177 8,357 9,499
EPS ($) 3.06 5.38 6.47
EPS without NRI ($) 3.06 5.38 6.47
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.61%
Dividends per Share ($) 2.38 2.50 2.43

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}